Key result
Perivascular FAI is linked to ~5% higher odds of significant LAD stenosis.
Why the study?
The association between lesion-specific perivascular fat attenuation index (FAI) and CCTA-defined anatomically significant (≥50%) LAD stenosis, as well as the diagnostic performance of a composite model integrating serum inflammatory biomarkers, needed investigation.
Does a composite model integrating lesion-specific perivascular fat attenuation index (FAI) and serum inflammatory biomarkers (hs-CRP, LDH, ApoA1/ApoB ratio) improve the discrimination of CCTA-defined anatomically significant (≥50%) LAD stenosis compared to individual biomarkers alone in patients with suspected CAD?
Observational (n=160)
Readers blinded to clinical and biomarker data
No
Does a composite model integrating lesion-specific perivascular fat attenuation index (FAI) and serum inflammatory biomarkers (hs-CRP, LDH, ApoA1/ApoB ratio) improve the discrimination of CCTA-defined anatomically significant (≥50%) LAD stenosis compared to individual biomarkers alone in patients with suspected CAD?
Odds Ratio: 1.055 (95% CI 1.014–1.098)
p-value: p=0.008
Higher (less negative) lesion-specific perivascular FAI values are independently associated with anatomically significant (≥50%) LAD stenosis on CCTA, and combining FAI with serum hs-CRP, LDH, and ApoA1/ApoB ratio significantly improves diagnostic discrimination over FAI or hs-CRP alone in a preliminary hypothesis-generating cohort.
FAI-biomarker models may enhance CCTA stenosis prediction; hypothesis-generating and requires prospective validation before clinical adoption.
Objective To investigate whether lesion-specific perivascular fat attenuation index (FAI) is associated with CCTA-defined anatomically significant (≥50%) left anterior descending coronary artery (LAD) stenosis and to evaluate the diagnostic performance of a composite model integrating serum inflammatory biomarkers. Methods We retrospectively analyzed 160 patients with suspected coronary artery disease (CAD) who underwent coronary computed tomography angiography (CCTA). Patients receiving anti-inflammatory medications were excluded. Lesion-specific perivascular FAI was measured around the LAD. The prespecified primary outcome was CCTA-defined anatomically significant LAD stenosis (≥50%), analysed as a binary variable. Multivariable logistic regression identified independent predictors, and the final model was internally evaluated with stratified 5-fold cross-validation, 10-fold cross-validation, and 1,000-bootstrap resampling. Model building was repeated within each resample. Calibration (slope, calibration-in-the-large, Brier score) and incremental discrimination (DeLong test) were assessed. Results Patients with CCTA-defined anatomically significant stenosis (≥50%) had higher, less negative FAI values, higher hs-CRP and LDH levels, and a lower ApoA1/ApoB ratio than those with stenosis <50% (all P < 0.05). FAI correlated with stenosis both as a continuous percentage ( ρ = 0.54, P < 0.001) and as a binary ≥50% variable ( ρ = 0.64, P < 0.001), with less negative FAI values accompanying more severe stenosis. The final model identified FAI (OR = 1.055, 95% CI: 1.014–1.098), hs-CRP (OR = 1.063, 95% CI: 1.005–1.125), LDH (OR = 1.014, 95% CI: 1.005–1.023), and the ApoA1/ApoB ratio (OR = 0.209, 95% CI: 0.070–0.624) as independent predictors. The composite model achieved an AUC of 0.915 (95% CI: 0.865–0.965); internal validation yielded AUCs of 0.872 (5-fold), 0.881 (95% CI: 0.826–0.936; 10-fold), and 0.895 (95% CI: 0.848–0.942; bootstrap). On formal DeLong testing for correlated ROC curves, the composite model showed significantly better discrimination than hs-CRP alone ( P = 0.020) and than FAI alone ( P < 0.001). Conclusions Higher, less negative perivascular FAI values were associated with CCTA-defined anatomically significant LAD stenosis. A composite model integrating FAI, hs-CRP, LDH, and the ApoA1/ApoB ratio showed high apparent diagnostic accuracy and remained stable across multiple internal validation strategies. Because this was a single-centre retrospective study without external validation or outcome data, these findings should be regarded as preliminary and hypothesis-generating; the model is not ready for clinical use.
No takes yet. Share an insight, caveat, or question.
Yiliya et al. (2026) conducted an observational in Suspected coronary artery disease with isolated left anterior descending coronary artery stenosis (n=160). Lesion-specific perivascular fat attenuation index (FAI) vs. LAD stenosis <50% vs ≥50% was evaluated on CCTA-defined anatomically significant left anterior descending coronary artery stenosis (≥50%) (OR 1.055, 95% CI 1.014-1.098, p=0.008). Perivascular FAI was independently associated with CCTA-defined anatomically significant (≥50%) LAD stenosis (OR 1.055, 95% CI 1.014-1.098, P=0.008), with a composite biomarker model reaching AUC 0.915.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: